MDGL
Madrigal Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Madrigal Pharmaceuticals, Inc. (MDGL) closed at $441.16 as of 2026-03-20, trading 66.2% above its 200-week moving average of $265.44. The stock is currently moving closer to the line, down from 68.8% last week. With a 14-week RSI of 22, MDGL is in oversold territory.
Trading volume is running at 1.3x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.83 ratio) is neutral — neither side is clearly dominating.
Over the past 949 weeks of data, MDGL has crossed below its 200-week moving average 15 times. On average, these episodes lasted 34 weeks. The average one-year return after crossing below was -4.7%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $10.1 billion, MDGL is a large-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -42.5%. The stock trades at 16.7x book value.
Share count has increased 26.2% over three years, indicating dilution.
Over the past 18.2 years, a hypothetical investment of $100 in MDGL would have grown to $160, compared to $661 for the S&P 500. MDGL has returned 2.6% annualized vs 10.9% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 2 open-market purchases totaling $61,921,024.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MDGL vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MDGL Crosses Below the Line?
Across 15 historical episodes, buying MDGL when it crossed below its 200-week moving average produced an average return of +13.8% after 12 months (median +6.0%), compared to +9.7% for the S&P 500 over the same periods. 53% of those episodes were profitable after one year. After 24 months, the average return was +20.7% vs +26.9% for the index.
Each line shows $100 invested at the moment MDGL crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MDGL has crossed below its 200-week MA 15 times with an average 1-year return of +-4.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2008 | Feb 2008 | 3 | 17.9% | +6.3% | +84.3% |
| Mar 2008 | Aug 2008 | 23 | 25.0% | -66.4% | +77.8% |
| Sep 2008 | Jan 2009 | 18 | 38.6% | -61.1% | +62.2% |
| Feb 2009 | Dec 2010 | 95 | 81.9% | -40.7% | +75.1% |
| Jan 2011 | Apr 2011 | 13 | 14.5% | -2.8% | +155.7% |
| Jun 2011 | Jan 2012 | 32 | 37.8% | +14.6% | +155.7% |
| Feb 2012 | May 2012 | 13 | 17.8% | +96.4% | +183.2% |
| Jun 2013 | Jul 2013 | 8 | 24.6% | -8.6% | +177.0% |
| Oct 2013 | Dec 2013 | 9 | 27.3% | -30.7% | +195.2% |
| Jan 2014 | Feb 2014 | 2 | 3.9% | -55.4% | +136.0% |
| Mar 2014 | Dec 2017 | 196 | 96.0% | -50.7% | +145.7% |
| Jan 2020 | Feb 2020 | 2 | 9.0% | +51.9% | +473.1% |
| Feb 2020 | May 2020 | 10 | 31.6% | +40.6% | +412.0% |
| May 2021 | Dec 2022 | 82 | 53.0% | -38.8% | +292.8% |
| Oct 2023 | Oct 2023 | 1 | 3.7% | +75.0% | +266.4% |
| Average | 34 | — | +-4.7% | — |
Frequently Asked Questions
Is MDGL below its 200-week moving average?
No. Madrigal Pharmaceuticals, Inc. (MDGL) is currently 66.2% above its 200-week moving average of $265.44. It would need to fall to $265.44 to cross below the line.
What is MDGL's 200-week moving average price?
Madrigal Pharmaceuticals, Inc.'s 200-week moving average is $265.44 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MDGL drops below its 200-week moving average?
MDGL has crossed below its 200-week moving average 15 times in our data. The average one-year return after these crossings was -4.7%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 34 weeks on average.
Is MDGL a good value right now?
Here's what our data says about MDGL as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 22 (oversold). Free cash flow is currently negative. Return on equity is -42.5%. Price-to-book is 16.7x. This is not a buy or sell recommendation — always do your own research.
How does MDGL compare to the S&P 500?
Over the past 18.2 years, $100 invested in MDGL would have grown to $160, compared to $661 for the S&P 500. That's 2.6% annualized vs 10.9% for the index. MDGL has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20